Feb 26, 2015 | News
The FACTS 001 trial was initiated to confirm the findings of CAPRISA 004, a phase IIB trial conducted in two sites in KwaZulu-Natal, which found that Tenofovir gel—used in a before and after sex regimen—reduced HIV infections by 39%. The FACTS 001 trial had a larger,...
